USD 18.95
(-0.26%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 139.82 Million USD | 20.35% |
2022 | 116.17 Million USD | 2.96% |
2021 | 112.84 Million USD | -13.91% |
2020 | 131.07 Million USD | 2092.24% |
2019 | 5.97 Million USD | 117.81% |
2018 | 2.74 Million USD | -6.15% |
2017 | 2.92 Million USD | -17.86% |
2016 | 3.56 Million USD | 419.1% |
2015 | 686 Thousand USD | 57.34% |
2014 | 436 Thousand USD | 0.0% |
2001 | - USD | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 103.23 Million USD | -26.16% |
2024 Q2 | 103.39 Million USD | 0.15% |
2023 Q2 | 91.25 Million USD | -15.39% |
2023 Q1 | 107.84 Million USD | -7.17% |
2023 Q3 | 96.56 Million USD | 5.82% |
2023 Q4 | 139.82 Million USD | 44.8% |
2023 FY | 139.82 Million USD | 20.35% |
2022 Q1 | 152.63 Million USD | 35.26% |
2022 Q4 | 116.17 Million USD | -6.6% |
2022 Q2 | 150.92 Million USD | -1.11% |
2022 FY | 116.17 Million USD | 2.96% |
2022 Q3 | 124.38 Million USD | -17.59% |
2021 Q1 | 197.51 Million USD | 50.69% |
2021 FY | 112.84 Million USD | -13.91% |
2021 Q4 | 112.84 Million USD | -29.57% |
2021 Q3 | 160.21 Million USD | 24.07% |
2021 Q2 | 129.13 Million USD | -34.62% |
2020 Q2 | 8.87 Million USD | 11.56% |
2020 Q3 | 60.35 Million USD | 580.3% |
2020 Q4 | 131.07 Million USD | 117.17% |
2020 FY | 131.07 Million USD | 2092.24% |
2020 Q1 | 7.95 Million USD | 33.02% |
2019 Q4 | 5.97 Million USD | -9.67% |
2019 Q2 | 5.29 Million USD | -6.98% |
2019 FY | 5.97 Million USD | 117.81% |
2019 Q1 | 5.69 Million USD | 107.32% |
2019 Q3 | 6.61 Million USD | 25.03% |
2018 Q2 | 2.98 Million USD | 23.69% |
2018 Q3 | 2.26 Million USD | -24.14% |
2018 FY | 2.74 Million USD | -6.15% |
2018 Q1 | 2.41 Million USD | -17.44% |
2018 Q4 | 2.74 Million USD | 21.14% |
2017 Q4 | 2.92 Million USD | -13.95% |
2017 Q2 | 3.07 Million USD | -12.83% |
2017 Q1 | 3.52 Million USD | -1.04% |
2017 FY | 2.92 Million USD | -17.86% |
2017 Q3 | 3.39 Million USD | 10.64% |
2016 Q1 | 1.13 Million USD | 64.87% |
2016 Q4 | 3.56 Million USD | -34.43% |
2016 Q3 | 5.43 Million USD | 7.01% |
2016 Q2 | 5.07 Million USD | 348.72% |
2016 FY | 3.56 Million USD | 419.1% |
2015 FY | 686 Thousand USD | 57.34% |
2015 Q4 | 686 Thousand USD | 0.0% |
2014 FY | 436 Thousand USD | 0.0% |
2001 FY | - USD | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Aspira Women's Health Inc. | 8.62 Million USD | -1520.76% |
bioAffinity Technologies, Inc. | 3.36 Million USD | -4053.614% |
Intelligent Bio Solutions Inc. | 5.59 Million USD | -2398.77% |
Standard BioTools Inc. | 159.86 Million USD | 12.537% |
Inotiv, Inc. | 588.04 Million USD | 76.222% |
Prenetics Global Limited | 44.01 Million USD | -217.684% |
Neuronetics, Inc. | 81.64 Million USD | -71.266% |
Star Equity Holdings, Inc. | 21.67 Million USD | -545.089% |
Castle Biosciences, Inc. | 86.54 Million USD | -61.567% |
Psychemedics Corporation | 6.59 Million USD | -2019.172% |
RadNet, Inc. | 2.07 Billion USD | 93.256% |
Exact Sciences Corporation | 3.32 Billion USD | 95.796% |
IDEXX Laboratories, Inc. | 1.77 Billion USD | 92.124% |
iSpecimen Inc. | 6.07 Million USD | -2200.454% |
OpGen, Inc. | 13.44 Million USD | -940.051% |
Exagen Inc. | 34.25 Million USD | -308.242% |
Bionano Genomics, Inc. | 118.24 Million USD | -18.247% |
CareDx, Inc | 223.28 Million USD | 37.38% |
Check-Cap Ltd. | 1.33 Million USD | -10413.008% |
Twist Bioscience Corporation | 152.97 Million USD | 8.595% |
Guardant Health, Inc. | 1.62 Billion USD | 91.41% |
Biodesix, Inc. | 94.51 Million USD | -47.936% |
BioNexus Gene Lab Corp. | 1.74 Million USD | -7926.851% |
Precipio, Inc. | 3.67 Million USD | -3707.816% |
Natera, Inc. | 691.79 Million USD | 79.788% |
Sera Prognostics, Inc. | 25.28 Million USD | -453.032% |
23andMe Holding Co. | 206.64 Million USD | 32.337% |
OPKO Health, Inc. | 622.47 Million USD | 77.538% |
Personalis, Inc. | 95.65 Million USD | -46.17% |
Aclaris Therapeutics, Inc. | 40.22 Million USD | -247.594% |
Applied DNA Sciences, Inc. | 8.77 Million USD | -1492.669% |
T2 Biosystems, Inc. | 62.83 Million USD | -122.531% |
Neogen Corporation | 1.44 Billion USD | 90.29% |
Myriad Genetics, Inc. | 312.9 Million USD | 55.314% |
ICON Public Limited Company | 7.74 Billion USD | 98.196% |
NeoGenomics, Inc. | 739.69 Million USD | 81.097% |
Star Equity Holdings, Inc. | 21.67 Million USD | -545.089% |
MDxHealth SA | 121.92 Million USD | -14.68% |
Prenetics Global Limited | 44.01 Million USD | -217.684% |
Illumina, Inc. | 4.36 Billion USD | 96.797% |
DarioHealth Corp. | 38.24 Million USD | -265.598% |
ENDRA Life Sciences Inc. | 1.09 Million USD | -12667.393% |
Medpace Holdings, Inc. | 1.09 Billion USD | 87.264% |
Mainz Biomed B.V. | 12.15 Million USD | -1049.879% |
Trinity Biotech plc | 83.38 Million USD | -67.686% |
Sotera Health Company | 2.68 Billion USD | 94.796% |
bioAffinity Technologies, Inc. | 3.36 Million USD | -4053.614% |